Should I buy Zimmer Biomet (ZBH) stock or is it too late?

Zimmer Biomet · Health Care · price $92

See the full Zimmer Biomet (ZBH) profile

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Bernstein — 69% of its targets hit on this sector (70 calls tested). It aims for $93 (+1.0 %), call made on August 7, 2026, maturing on August 7, 2027 (68 d ago).

The 5 reliable analysts $100+8.6 %

The 7 other firms $95+3.2 %

How to read it: the 5 reliable firms are not filtered by optimism — 5 aim above the price, 0 below, hence their $100 median. “The 7 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Zimmer Biomet

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Citigroup	71 %	+10.3 %	14	$93 +1%
UBS	57 %	+9.7 %	7	$86 -7%
Stifel	31 %	+6.0 %	16	$110 +19%
BTIG	33 %	+3.0 %	6	$112 +22%
Barclays	57 %	+0.3 %	14	$100 +9%
Raymond James	33 %	+0.2 %	21	$113 +23%
Wells Fargo	38 %	-1.2 %	8	$90 -2%
JMP Securities	36 %	-4.6 %	14	$125 +36%

In short — Should you invest in Zimmer Biomet? Is it too late, still worth it? Analysts are split (33% buy, median target $100, i.e. +9%), and the most reliable on ZBH targets even higher. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

Median price target $100, i.e. +9% from the current price ($92).
The most reliable firm on ZBH, Truist Securities (100% hit rate, 2 scored calls), targets $106 (call made on August 7, 2026, maturing on August 7, 2027) (+15%) in its most recent call, and $92 (call made on April 29, 2026, maturing on April 29, 2027) (+0%) in the one coming due soonest.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 12 ratings, 8 are neutral.
A 12-month target is not a guaranteed path: the price can fall in the meantime.

The analyst consensus on ZBH

Median target $100 (+9%) · 12 ratings · Hold consensus

Strong Buy00%

Buy433%

Hold867%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Zimmer Biomet now?

We won't decide for you. The facts: 33% of analysts rate it a buy, median target $100 (+9%), and Truist Securities (most reliable on ZBH, 100%) targets $106. Weigh that against valuation (P/E ~22). This is not personalized advice.

Is it too late to invest in Zimmer Biomet?

Not according to analysts: the median target ($100) is still +9% above the current price ($92) (most reliable on ZBH: Truist Securities, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Zimmer Biomet still worth investing in?

It depends on the gap between the price ($92) and its estimated value: analysts target $100 on median (+9%), with 33% buys (most reliable on ZBH: Truist Securities, 100%). Cross-check with their real reliability on ZBH and the cautions above. Information, not advice.

What's the main risk in buying ZBH?

The consensus is not unanimous: of 12 ratings, 8 are neutral.

→ Go deeper: the full Zimmer Biomet profile (consensus, analyst reliability, price target, performance).